

**Supplementary Table 1.** ACR20, ACR50, and ACR70 response rates by treatment sequence in the Mexican Phase 3 study population over time (FAS, no imputation)

Month	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Placebo
<b>ACR20, % (n/N)</b> <b>[95% CI]</b>			
1	56.8 (21/37) [39.5, 72.9]	66.7 (36/54) [52.5, 78.9]	38.5 (10/26) [20.2, 59.4]
3	69.4 (25/36) [51.9, 83.7]	70.4 (38/54) [56.4, 82.0]	26.9 (7/26) [11.6, 47.8]
6	73.5 (25/34) [55.6, 87.1]	81.5 (44/54) [68.6, 90.8]	60.0 (6/10) [26.2, 87.8]
9	71.4 (15/21) [47.8, 88.7]	82.5 (33/40) [67.2, 92.7]	-
12	77.8 (14/18) [52.4, 93.6]	78.9 (30/38) [62.7, 90.5]	-
<b>ACR50, % (n/N)</b> <b>[95% CI]</b>			
1	29.7 (11/37) [15.9, 47.0]	27.8 (15/54) [16.5, 41.6]	7.7 (2/26) [1.0, 25.1]
3	55.6 (20/36) [38.1, 72.1]	50.0 (27/54) [36.1, 63.9]	11.5 (3/26) [2.5, 30.2]
6	61.8 (21/34) [43.6, 77.8]	59.3 (32/54) [45.0, 72.4]	40.0 (4/10) [12.2, 73.8]
9	47.6 (10/21) [25.7, 70.2]	62.5 (25/40) [45.8, 77.3]	-
12	61.1 (11/18) [35.8, 82.7]	65.8 (25/38) [48.7, 80.4]	-

ACR70, % (n/N) [95% CI]			
1	13.5 (5/37) [4.5, 28.8]	5.6 (3/54) [1.2, 15.4]	7.7 (2/26) [1.0, 25.1]
3	25.0 (9/36) [12.1, 42.2]	20.4 (11/54) [10.6, 33.5]	3.8 (1/26) [0.1, 19.6]
6	44.1 (15/34) [27.2, 62.1]	37.0 (20/54) [24.3, 51.3]	0.0 (0/10) [0.0, 30.9]
9	42.9 (9/21) [21.8, 66.0]	45.0 (18/40) [29.3, 61.5]	-
12	38.9 (7/18) [17.3, 64.3]	52.6 (20/38) [35.8, 69.0]	-

ACR, American College of Rheumatology; BID, twice daily; FAS, full analysis set; CI, confidence interval; N, number of evaluable patients at time point of interest; n, number of patients with response.

**Supplementary Table 2.** Mean (95% CI) change from baseline in DAS28-4(ESR) and mean (95% CI) change from baseline in HAQ-DI score by treatment sequence in the Mexican Phase 3 study population over time (FAS, no imputation)

Month	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Placebo
<b>Change from baseline in DAS28-4(ESR), mean [95% CI]</b> (N)			
1	-1.07 [-1.6, -0.6] (10)	-1.31 [-1.8, -0.8] (21)	-1.06 [-1.7, -0.4] (14)
3	-2.43 [-2.9, -1.9] (34)	-2.16 [-2.5, -1.8] (49)	-1.03 [-1.5, -0.6] (26)
6	-2.20 [-2.8, -1.6] (33)	-2.54 [-2.9, -2.2] (51)	-1.37 [-2.3, -0.5] (10)
9	-1.96 [-2.9, -1.0] (10)	-2.49 [-2.9, -2.1] (21)	-
12	-2.39 [-3.0, -1.8] (17)	-2.68 [-3.2, -2.1] (36)	-
<b>Change from baseline in HAQ-DI, mean [95% CI]</b> (N)			
1	-0.47 [-0.6, -0.3] (37)	-0.61 [-0.8, -0.5] (54)	-0.13 [-0.3, 0.0] (26)
3	-0.59 [-0.8, -0.4] (36)	-0.78 [-1.0, -0.6] (54)	-0.28 [-0.5, -0.1] (26)
6	-0.64 [-0.9, -0.4] (34)	-0.90 [-1.1, -0.7] (54)	-0.25 [-0.7, 0.2] (10)
9	-0.78 [-1.1, -0.5] (21)	-1.04 [-1.2, -0.9] (40)	-
12	-0.74 [-1.1, -0.4] (18)	-0.99 [-1.2, -0.8] (38)	-

BID, twice daily; CI, confidence interval; DAS28-4(ESR), Disease Activity Score (erythrocyte sedimentation rate); FAS, full analysis set; HAQ-DI, Health Assessment Questionnaire-Disability Index; N, number of evaluable patients at time point of interest.

**Supplementary Table 3.** ACR20, ACR50, and ACR70 response rates in the Mexican LTE study population over time (FAS, no imputation)

Month	ACR20, % (n/N) [95% CI]		ACR50, % (n/N) [95% CI]		ACR70, % (n/N) [95% CI]	
	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID
1	64.71 (55/85) [53.6, 74.8]	79.20 (99/125) [71.0, 85.9]	40.00 (34/85) [29.5, 51.2]	52.80 (66/125) [43.7, 61.8]	15.29 (13/85) [8.4, 24.7]	31.20 (39/125) [23.2, 40.1]
3	67.86 (57/84) [56.8, 77.6]	82.11 (101/123) [74.2, 88.4]	53.57 (45/84) [42.4, 64.5]	65.04 (80/123) [55.9, 73.4]	20.24 (17/84) [12.3, 30.4]	34.96 (43/123) [26.6, 44.1]
6	65.48 (55/84) [54.3, 75.5]	81.82 (99/121) [73.8, 88.2]	46.43 (39/84) [35.5, 57.7]	61.16 (74/121) [51.9, 69.9]	29.76 (25/84) [20.3, 40.7]	44.63 (54/121) [35.6, 53.9]
9	70.37 (57/81) [59.2, 80.0]	76.58 (85/111) [67.6, 84.1]	58.02 (47/81) [46.5, 68.9]	55.86 (62/111) [46.1, 65.3]	37.04 (30/81) [26.6, 48.5]	40.54 (45/111) [31.3, 50.3]
12	71.79 (56/78) [60.5, 81.4]	74.53 (79/106) [65.1, 82.5]	51.28 (40/78) [39.7, 62.8]	59.43 (63/106) [49.5, 68.9]	26.92 (21/78) [17.5, 38.2]	46.23 (49/106) [36.5, 56.2]
15	81.08 (60/74) [70.3, 89.3]	79.80 (79/99) [70.5, 87.2]	59.46 (44/74) [47.4, 70.7]	65.66 (65/99) [55.4, 74.9]	28.38 (21/74) [18.5, 40.1]	45.45 (45/99) [35.4, 55.8]
18	74.65 (53/71) [62.9, 84.2]	72.62 (61/84) [61.8, 81.8]	54.93 (39/71) [42.7, 66.8]	60.71 (51/84) [49.5, 71.2]	36.62 (26/71) [25.5, 48.9]	46.43 (39/84) [35.5, 57.7]
21	74.29 (52/70) [62.4, 84.0]	71.23 (52/73) [59.5, 81.2]	55.71 (39/70) [43.3, 67.6]	57.53 (42/73) [45.4, 69.0]	32.86 (23/70) [22.1, 45.1]	46.58 (34/73) [34.8, 58.6]
24	80.30 (53/66) [68.7, 89.1]	74.24 (49/66) [62.0, 84.2]	59.09 (39/66) [46.3, 71.1]	57.58 (38/66) [44.8, 69.7]	36.36 (24/66) [24.9, 49.1]	42.42 (28/66) [30.3, 55.2]
27	77.42 (48/62) [65.0, 87.1]	76.47 (39/51) [62.5, 87.2]	56.45 (35/62) [43.3, 69.0]	64.71 (33/51) [50.1, 77.6]	37.10 (23/62) [25.2, 50.3]	47.06 (24/51) [32.9, 61.5]

30	84.75	72.22	72.88	52.78	45.76	44.44
	(50/59)	(26/36)	(43/59)	(19/36)	(27/59)	(16/36)
	[73.0, 92.8]	[54.8, 85.8]	[59.7, 83.6]	[35.5, 69.6]	[32.7, 59.3]	[27.9, 61.9]
33	83.05	79.17	59.32	58.33	37.29	50.00
	(49/59)	(19/24)	(35/59)	(14/24)	(22/59)	(12/24)
	[71.0, 91.6]	[57.9, 92.9]	[45.8, 71.9]	[36.6, 77.9]	[25.0, 50.9]	[29.1, 70.9]
36	78.95	80.00	61.40	66.67	33.33	60.00
	(45/57)	(12/15)	(35/57)	(10/15)	(19/57)	(9/15)
	[66.1, 88.6]	[51.9, 95.7]	[47.6, 74.0]	[38.4, 88.2]	[21.4, 47.1]	[32.3, 83.7]

---

ACR, American College of Rheumatology; BID, twice daily; CI, confidence interval; FAS,

full analysis set; LTE, long-term extension; N, number of evaluable patients at time point of interest.

**Supplementary Table 4.** Mean (95% CI) change from baseline in DAS28-4(ESR) and mean (95% CI) change from baseline in HAQ-DI score in the Mexican LTE study population over time (FAS, no imputation)

Month	Change from baseline in DAS28-4(ESR), mean [95% CI] (N)		Change from baseline in HAQ-DI, mean [95% CI] (N)	
	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID
1	-1.74 [-2.0, -1.5] (66)	-2.43 [-2.7, -2.2] (124)	-0.59 [-0.7, -0.4] (85)	-0.63 [-0.8, -0.5] (124)
3	-1.92 [-2.3, -1.6] (67)	-2.77 [-3.0, -2.5] (123)	-0.58 [-0.7, -0.4] (84)	-0.70 [-0.8, -0.6] (123)
6	-1.89 [-2.2, -1.6] (66)	-2.86 [-3.1, -2.6] (121)	-0.62 [-0.8, -0.5] (83)	-0.69 [-0.8, -0.6] (121)
9	-2.19 [-2.5, -1.9] (61)	-2.78 [-3.1, -2.5] (108)	-0.65 [-0.8, -0.5] (80)	-0.63 [-0.8, -0.5] (111)
12	-2.15 [-2.5, -1.8] (60)	-2.90 [-3.2, -2.6] (103)	-0.68 [-0.8, -0.5] (78)	-0.64 [-0.8, -0.5] (104)
15	-2.25 [-2.6, -1.9] (55)	-2.89 [-3.2, -2.6] (98)	-0.65 [-0.8, -0.5] (74)	-0.72 [-0.9, -0.6] (98)
18	-2.21 [-2.6, -1.9] (52)	-2.77 [-3.1, -2.4] (83)	-0.66 [-0.8, -0.5] (69)	-0.67 [-0.9, -0.5] (83)
21	-2.07 [-2.5, -1.7] (53)	-2.61 [-3.0, -2.3] (72)	-0.69 [-0.9, -0.5] (69)	-0.60 [-0.8, -0.4] (72)
24	-2.25 [-2.6, -1.9] (50)	-2.63 [-2.9, -2.3] (66)	-0.68 [-0.8, -0.5] (66)	-0.56 [-0.7, -0.4] (66)
27	-2.33 [-2.7, -1.9] (45)	-3.02 [-3.4, -2.7] (51)	-0.72 [-0.9, -0.6] (62)	-0.57 [-0.8, -0.4] (51)
30	-2.56 [-3.0, -2.1] (42)	-3.06 [-3.5, -2.7] (33)	-0.68 [-0.9, -0.5] (59)	-0.40 [-0.7, -0.1] (36)
33	-2.43 [-2.8, -2.1] (43)	-2.66 [-3.1, -2.2] (24)	-0.81 [-1.0, -0.6] (59)	-0.32 [-0.6, -0.1] (24)

36	-2.49 [-2.9, -2.1] (40)	-2.99 [-3.7, -2.3] (15)	-0.75 [-0.9, -0.6] (57)	-0.39 [-0.8, 0.0] (15)
----	----------------------------	----------------------------	----------------------------	---------------------------

BID, twice daily; CI, confidence interval; DAS28-4(ESR), Disease Activity Score (erythrocyte sedimentation rate); FAS, full analysis set; HAQ-DI, Health Assessment Questionnaire-Disability Index; LTE, long-term extension; N, number of evaluable patients at time point of interest.



**Supplementary Table 5A.** Mean change from baseline in hemoglobin and neutrophil count, and mean absolute lymphocyte count, in the Mexican Phase 3 study population over time

Month	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Placebo
<b>Change from baseline in hemoglobin (g/dL), mean (SE)</b> (N)			
1	0.15 (0.12) (37)	0.01 (0.09) (54)	-0.13 (0.20) (26)
3	0.19 (0.13) (36)	-0.25 (0.11) (53)	-0.06 (0.21) (25)
6	0.15 (0.16) (41)	-0.13 (0.12) (63)	-0.60 (0.45) (10)
9	0.67 (0.20) (30)	0.06 (0.17) (48)	
12	0.86 (0.22) (28)	0.30 (0.17) (47)	
<b>Change from baseline neutrophil count (<math>10^3/\text{mm}^3</math>), mean (SE)</b> (N)			
1	-0.52 (0.38) (37)	-0.84 (0.27) (54)	-0.08 (0.27) (26)
3	-0.73 (0.29) (36)	-0.89 (0.26) (53)	-0.16 (0.25) (25)
6	-0.87 (0.21) (41)	-1.06 (0.23) (63)	-0.01 (0.54) (10)
9	-0.33 (0.34) (30)	-0.82 (0.26) (48)	
12	-0.17 (0.38) (28)	-0.26 (0.30) (47)	
<b>Absolute lymphocyte count (<math>10^3/\text{mm}^3</math>), mean (SE)</b> (N)			
0	1.74 (0.10) (37)	1.70 (0.10) (55)	1.84 (0.18) (27)

1	1.82 (0.12) (37)	1.90 (0.12) (54)	1.77 (0.17) (26)
3	1.76 (0.10) (36)	1.73 (0.10) (53)	1.96 (0.17) (25)
6	1.70 (0.11) (41)	1.71 (0.11) (63)	1.72 (0.20) (10)
9	1.83 (0.16) (30)	1.73 (0.11) (48)	
12	1.65 (0.13) (28)	1.37 (0.09) (47)	

---

BID, twice daily; N, number of evaluable patients at time point of interest; SE, standard error.

**Supplementary Table 5B.** Mean change from baseline in hemoglobin and neutrophil count, and mean absolute lymphocyte count, in the Mexican LTE study population over time

Month	Change from baseline in hemoglobin (g/dL), mean (SE) (N)		Change from baseline neutrophil count ( $10^3/\text{mm}^3$ ), mean (SE) (N)		Absolute lymphocyte count ( $10^3/\text{mm}^3$ ), mean (SE) (N)	
	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID
0	-	-	-	-	2.00 (0.08) (86)	1.63 (0.06) (126)
1	0.10 (0.12) (85)	0.07 (0.10) (124)	-0.93 (0.20) (85)	-0.75 (0.15) (124)	2.12 (0.07) (85)	1.68 (0.06) (124)
3	-0.09 (0.15) (85)	-0.02 (0.10) (122)	-0.79 (0.17) (84)	-0.56 (0.18) (122)	1.98 (0.07) (84)	1.57 (0.06) (122)
12	0.20 (0.15) (78)	0.11 (0.13) (103)	-1.31 (0.22) (78)	-0.6 (0.19) (103)	1.62 (0.05) (78)	1.4 (0.06) (103)
18	0.48 (0.18) (69)	0.23 (0.13) (83)	-1.17 (0.26) (69)	-0.87 (0.16) (83)	1.51 (0.07) (69)	1.33 (0.06) (83)
24	0.45 (0.21) (66)	0.09 (0.16) (62)	-1.52 (0.21) (66)	-0.80 (0.20) (62)	1.45 (0.07) (66)	1.23 (0.05) (62)
30	0.56 (0.23) (57)	0.03 (0.21) (35)	-1.17 (0.24) (57)	-1.18 (0.34) (35)	1.53 (0.07) (57)	1.11 (0.07) (35)
36	0.28 (0.24) (57)	0.42 (0.57) (11)	-1.37 (0.24) (57)	-0.72 (0.69) (11)	1.40 (0.06) (57)	1.07 (0.11) (11)
42	0.46 (0.20) (54)		-1.24 (0.25) (54)		1.36 (0.06) (54)	
48	0.65 (0.20) (52)		-1.04 (0.29) (52)		1.43 (0.08) (52)	
54	0.66 (0.18) (47)		-1.47 (0.24) (47)		1.34 (0.07) (47)	
60	0.37 (0.22) (43)		-1.12 (0.27) (43)		1.36 (0.09) (43)	

66	0.84 (0.23) (32)	-1.48 (0.31) (32)	1.29 (0.08) (32)
72	0.54 (0.34) (12)	-0.91 (0.46) (12)	1.17 (0.10) (12)

BID, twice daily; LTE, long-term extension; N, number of evaluable patients at time point of interest; SE, standard error.